FDA grants pri­or­i­ty re­view to Lyn­parza com­bo ther­a­py for metasta­t­ic prostate can­cer

As­traZeneca and Mer­ck’s top-sell­ing PARP in­hibitor Lyn­parza is pos­si­bly on its way to win­ning reg­u­la­to­ry ap­proval for yet an­oth­er in­di­ca­tion.

The FDA has ac­cept­ed the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER